Fibroblast growth factor 21 is a hepatokine involved in MASLD progression

Abstract Aim We aimed to assess the role of FGF21 in metabolic dysfunction‐associated steatotic liver disease (MASLD) at a multi‐scale level. Methods We used human MASLD pathology samples for FGF21 gene expression analyses (qPCR and RNAseq), serum to measure circulating FGF21 levels and DNA for genotyping the FGF21 rs838133 variant in both estimation and validation cohorts. A hepatocyte‐derived cell line was exposed to free fatty acids at different timepoints. Finally, C57BL/6J mice were fed a high‐fat and choline‐deficient diet (CDA‐HFD) for 16 weeks to assess hepatic FGF21 protein expression and FGF21 levels by ELISA. Results A significant upregulation in FGF21 mRNA expression was observed in the liver analysed by both qPCR (fold change 5.32 ± 5.25 vs . 0.59 ± 0.66; p = 0.017) and RNA‐Seq (3.5 fold; FDR: 0.006; p < 0.0001) in MASLD patients vs . controls. Circulating levels of FGF21 were increased in patients with steatohepatitis vs . bland steatosis (386.6 ± 328.9 vs . 297.9 ± 231.5 pg/mL; p = 0.009). Besides, sex, age, A‐allele from FGF21, GG genotype from PNPLA3, ALT, type 2 diabetes mellitus and BMI were independently associated with MASH and significant fibrosis in both estimation and validation cohorts. In vitro exposure of Huh7.5 cells to high concentrations of free fatty acids (FFAs) resulted in overexpression of FGF21 ( p < 0.001). Finally, Circulating FGF21 levels and hepatic FGF21 expression were found to be significantly increased ( p < 0.001) in animals under CDA‐HFD. Conclusions Hepatic and circulating FGF21 expression was increased in MASH patients, in Huh7.5 cells under FFAs and in CDA‐HFD animals. The A‐allele from the rs838133 variant was also associated with an increased risk of steatohepatitis and significant and advanced fibrosis in MASLD patients.